002349 精华制药
已收盘 04-30 15:00:00
资讯
新帖
简况
图解精华制药一季报：第一季度单季净利润同比增长5.87%
证券之星 · 04-29 19:12
图解精华制药一季报：第一季度单季净利润同比增长5.87%
精华制药(002349)3月31日股东户数8.07万户，较上期减少3.79%
证券之星 · 04-29 17:52
精华制药(002349)3月31日股东户数8.07万户，较上期减少3.79%
精华制药（002349）2025年年报简析：营收净利润同比双双增长，盈利能力上升
证券之星 · 04-24
精华制药（002349）2025年年报简析：营收净利润同比双双增长，盈利能力上升
精华制药（002349）披露“质量回报双提升”行动方案，4月23日股价下跌2.04%
证券之星 · 04-23
精华制药（002349）披露“质量回报双提升”行动方案，4月23日股价下跌2.04%
精华制药(002349)3月31日股东户数8.07万户，较上期减少3.79%
证券之星 · 04-22
精华制药(002349)3月31日股东户数8.07万户，较上期减少3.79%
股市必读：精华制药（002349）3月23日收盘跌8.13%，主力净流入1461.69万元
证券之星 · 03-24
股市必读：精华制药（002349）3月23日收盘跌8.13%，主力净流入1461.69万元
精华制药：公司现金流状况良好
证券之星 · 02-05
精华制药：公司现金流状况良好
精华制药最新公告：孙公司宁夏森萱因污染环境罪被判处罚金五十万元
证券之星 · 2025-12-25
精华制药最新公告：孙公司宁夏森萱因污染环境罪被判处罚金五十万元
精华制药：玛巴洛沙韦尚未具备商业化生产销售条件
证券之星 · 2025-12-09
精华制药：玛巴洛沙韦尚未具备商业化生产销售条件
精华制药：二氧五环产销量基本保持平稳
证券之星 · 2025-12-09
精华制药：二氧五环产销量基本保持平稳
精华制药：正柴胡饮颗粒入选流感治疗指南
证券之星 · 2025-12-08
精华制药：正柴胡饮颗粒入选流感治疗指南
精华制药：正柴胡饮颗粒入选多版流感治疗指南
证券之星 · 2025-11-13
精华制药：正柴胡饮颗粒入选多版流感治疗指南
精华制药（002349）披露公司产品获得药品注册证书，11月11日股价上涨0.25%
证券之星 · 2025-11-11
精华制药（002349）披露公司产品获得药品注册证书，11月11日股价上涨0.25%
精华制药(002349.SZ)：卡左双多巴缓释片获得药品注册证书
智通财经 · 2025-11-11
精华制药(002349.SZ)：卡左双多巴缓释片获得药品注册证书
股市必读：精华制药（002349）10月31日董秘有最新回复
证券之星 · 2025-11-03
股市必读：精华制药（002349）10月31日董秘有最新回复
精华制药：为遵循信息披露公平原则,公司会在定期报告披露相对应时点股东人数
证券之星 · 2025-03-06
精华制药：为遵循信息披露公平原则,公司会在定期报告披露相对应时点股东人数
精华制药：公司尚在进行项目前期可行性方案论证等工作
证券之星 · 2025-02-18
精华制药：公司尚在进行项目前期可行性方案论证等工作
精华制药：2023年度公司及下属子公司环境治理和保护的投入累积约2932万元
证券之星 · 2025-02-07
精华制药：2023年度公司及下属子公司环境治理和保护的投入累积约2932万元
精华制药收盘下跌2.60%，滚动市盈率29.59倍
金融界 · 2024-12-25
精华制药收盘下跌2.60%，滚动市盈率29.59倍
加载更多
公司概况
公司名称：
精华制药集团股份有限公司
所属行业：
医药制造业
上市日期：
2010-02-03
主营业务：
精华制药集团股份有限公司的主营业务是传统中成药制剂、化学原料药及中间体、化工医药中间体、中药材及中药饮片、大健康产品等的研发、生产和销售。公司的主要产品是王氏保赤丸、季德胜蛇药片、正柴胡饮颗粒、黄芪泡腾片、当归、白芍、苯巴比妥、氟尿嘧啶、二氧六环、甲基肼。
发行价格：
19.80
{"stockData":{"symbol":"002349","market":"SZ","secType":"STK","nameCN":"精华制药","latestPrice":7.52,"timestamp":1777532595000,"preClose":7.31,"halted":0,"volume":19758643,"delay":0,"changeRate":0.0287,"floatShares":814000000,"shares":830000000,"eps":0.2688,"marketStatus":"已收盘","change":0.21,"latestTime":"04-30 15:00:00","open":7.36,"high":7.59,"low":7.34,"amount":148000000,"amplitude":0.0342,"askPrice":7.52,"askSize":1914,"bidPrice":7.51,"bidSize":976,"shortable":0,"etf":0,"ttmEps":0.2688,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1778031000000},"marketStatusCode":5,"adr":0,"adjPreClose":7.31,"symbolType":"stock","openAndCloseTimeList":[[1777512600000,1777519800000],[1777525200000,1777532400000]],"highLimit":8.04,"lowLimit":6.58,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":829674908,"isCdr":false,"pbRate":2.2,"roa":"--","peRate":27.97619,"roe":"2.36%","epsLYR":0.2678,"committee":-0.555182,"marketValue":6239000000,"turnoverRate":0.0243,"status":0,"floatMarketCap":6123000000},"requestUrl":"/m/hq/s/002349","defaultTab":"news","newsList":[{"id":"2631518418","title":"图解精华制药一季报：第一季度单季净利润同比增长5.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=2631518418","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631518418?lang=zh_cn&edition=full","pubTime":"2026-04-29 19:12","pubTimestamp":1777461154,"startTime":"0","endTime":"0","summary":"证券之星消息，精华制药2026年一季报显示，一季度公司主营收入3.8亿元，同比上升4.46%；归母净利润6587.25万元，同比上升5.87%；扣非净利润6382.35万元，同比上升5.76%；负债率10.81%，投资收益71.15万元，财务费用-317.61万元，毛利率55.39%。财报数据概要请见下图:以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042900059747.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002349"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631596720","title":"精华制药(002349)3月31日股东户数8.07万户，较上期减少3.79%","url":"https://stock-news.laohu8.com/highlight/detail?id=2631596720","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631596720?lang=zh_cn&edition=full","pubTime":"2026-04-29 17:52","pubTimestamp":1777456370,"startTime":"0","endTime":"0","summary":"证券之星消息，近日精华制药披露，截至2026年3月31日公司股东户数为8.07万户，较12月31日减少3181.0户，减幅为3.79%。在中药行业个股中，精华制药股东户数高于行业平均水平，截至3月31日，中药行业平均股东户数为5.36万户。从股价来看，2025年12月31日至2026年3月31日，精华制药区间涨幅为0.83%，在此期间股东户数减少3181.0户，减幅为3.79%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042900056182.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0102","002349","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629402718","title":"精华制药（002349）2025年年报简析：营收净利润同比双双增长，盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2629402718","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629402718?lang=zh_cn&edition=full","pubTime":"2026-04-24 22:32","pubTimestamp":1777041172,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期精华制药发布2025年年报。截至本报告期末，公司营业总收入14.6亿元，同比上升4.13%，归母净利润2.19亿元，同比上升3.12%。按单季度数据看，第四季度营业总收入3.68亿元，同比上升3.01%，第四季度归母净利润4291.21万元，同比下降11.37%。本报告期精华制药盈利能力上升，毛利率同比增幅4.45%，净利率同比增幅1.61%。本次财报公布的各项数据指标表现尚佳。去年的净利率为17.93%，算上全部成本后，公司产品或服务的附加值高。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042400065273.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002349"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629824368","title":"精华制药（002349）披露“质量回报双提升”行动方案，4月23日股价下跌2.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629824368","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629824368?lang=zh_cn&edition=full","pubTime":"2026-04-23 17:55","pubTimestamp":1776938144,"startTime":"0","endTime":"0","summary":"截至2026年4月23日收盘，精华制药报收于7.22元，较前一交易日下跌2.04%，最新总市值为59.9亿元。该股当日开盘7.33元，最高7.36元，最低7.2元，成交额达1.11亿元，换手率为1.88%。公告显示，公司为落实稳市场、稳信心政策，制定“质量回报双提升”行动方案。通过现金分红、股权激励、股份回购、并购重组等方式加强市值管理，提升股东回报。2025年实施首期限制性股票激励计划，覆盖105人，授予1549.4万股。注重信息披露质量与投资者关系管理，多渠道开展交流。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042300049504.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0102","002349"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629019072","title":"精华制药(002349)3月31日股东户数8.07万户，较上期减少3.79%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629019072","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629019072?lang=zh_cn&edition=full","pubTime":"2026-04-22 17:28","pubTimestamp":1776850093,"startTime":"0","endTime":"0","summary":"证券之星消息，近日精华制药披露，截至2026年3月31日公司股东户数为8.07万户，较12月31日减少3181.0户，减幅为3.79%。在中药行业个股中，精华制药股东户数高于行业平均水平，截至3月31日，中药行业平均股东户数为5.35万户。从股价来看，2025年12月31日至2026年3月31日，精华制药区间涨幅为0.83%，在此期间股东户数减少3181.0户，减幅为3.79%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042200040586.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002349","BK0102"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621859220","title":"股市必读：精华制药（002349）3月23日收盘跌8.13%，主力净流入1461.69万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2621859220","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621859220?lang=zh_cn&edition=full","pubTime":"2026-03-24 02:00","pubTimestamp":1774288856,"startTime":"0","endTime":"0","summary":"截至2026年3月23日收盘，精华制药报收于6.78元，下跌8.13%，换手率4.53%，成交量36.87万手，成交额2.57亿元。交易信息汇总精华制药3月23日收盘价为6.78元，下跌8.13%，当日成交金额3687.34万元。该股已连续3个交易日下跌。前10个交易日内，主力资金累计净流入205.2万元，期间股价累计下跌10.48%；融资余额累计减少554.83万元，融券余量累计减少1.36万股。3月23日单日资金流向显示，主力资金净流入1461.69万元，游资资金净流入1323.92万元，散户资金净流出2785.61万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032400001848.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002349","BK0102"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609106143","title":"精华制药：公司现金流状况良好","url":"https://stock-news.laohu8.com/highlight/detail?id=2609106143","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609106143?lang=zh_cn&edition=full","pubTime":"2026-02-05 08:45","pubTimestamp":1770252311,"startTime":"0","endTime":"0","summary":"证券之星消息，精华制药02月04日在投资者关系平台上答复投资者关心的问题。公司将在2026年4月23日披露2025年年度报告，请您关注。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020500006422.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002349","159399","BK0102"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2594231153","title":"精华制药最新公告：孙公司宁夏森萱因污染环境罪被判处罚金五十万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2594231153","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594231153?lang=zh_cn&edition=full","pubTime":"2025-12-25 19:41","pubTimestamp":1766662871,"startTime":"0","endTime":"0","summary":"精华制药(002349.SZ)公告称，公司孙公司宁夏森萱药业有限公司因污染环境罪被判处罚金人民币五十万元，与已缴纳的罚款九十万元折抵后，无需再行缴纳。案件涉案金额较小，不会对公司2025年净利润产生重大影响。且宁夏森萱本案所述行为发生后高度重视，积极整改，已于2024年7月恢复正常生产经营。此案件司法裁判结果不会导致公司触及重大违法强制退市情形。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122500030505.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002349","BK0102"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2590839950","title":"精华制药：玛巴洛沙韦尚未具备商业化生产销售条件","url":"https://stock-news.laohu8.com/highlight/detail?id=2590839950","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590839950?lang=zh_cn&edition=full","pubTime":"2025-12-09 11:37","pubTimestamp":1765251459,"startTime":"0","endTime":"0","summary":"证券之星消息，精华制药(002349)12月09日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘好，公司玛巴洛沙韦还在改进中，是不是意味着短期无法投放市场？精华制药回复：公司玛巴洛沙韦产品工艺优化工作尚在推进中，目前还未具备商业化生产销售的条件。感谢您对公司的关心！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120900013670.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002349","BK0102"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2590862399","title":"精华制药：二氧五环产销量基本保持平稳","url":"https://stock-news.laohu8.com/highlight/detail?id=2590862399","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590862399?lang=zh_cn&edition=full","pubTime":"2025-12-09 11:37","pubTimestamp":1765251458,"startTime":"0","endTime":"0","summary":"证券之星消息，精华制药(002349)12月09日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘好，公司二氧五环跟电解液高度关联，锂电池行业目前来说发展势头不错，为何公司二氧五环没有涨价？不符合客观逻辑啊，目前二氧五环是满产满销吗？精华制药回复：公司孙公司二氧五环产品主要应用与共聚甲醛的合成，小部分用于磷酸铁锂路线一次电池的电解液，该产品的定价参照市场需求确定，其产销量基本保持平稳。感谢您对公司的关心！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120900013667.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002349","BK0102","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2589135821","title":"精华制药：正柴胡饮颗粒入选流感治疗指南","url":"https://stock-news.laohu8.com/highlight/detail?id=2589135821","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589135821?lang=zh_cn&edition=full","pubTime":"2025-12-08 20:51","pubTimestamp":1765198280,"startTime":"0","endTime":"0","summary":"证券之星消息，精华制药12月08日在投资者关系平台上答复投资者关心的问题。请问公司目前产品可以应用于今年甲流的治疗有哪些？以上产品在医院及药房均可购买，感谢您对公司的关心。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120800031680.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0102","002349","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2583560902","title":"精华制药：正柴胡饮颗粒入选多版流感治疗指南","url":"https://stock-news.laohu8.com/highlight/detail?id=2583560902","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583560902?lang=zh_cn&edition=full","pubTime":"2025-11-13 20:51","pubTimestamp":1763038298,"startTime":"0","endTime":"0","summary":"证券之星消息，精华制药11月12日在投资者关系平台上答复投资者关心的问题。为何公司股价长期低迷，公司的产品对流感是否有疗效。为何市场不待见精华制药，公司两家上市企业，三个季度1.7亿多净利润，公司估值才六十几亿，严重低估。公司将继续以良好的业绩来回报广大投资者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111300039892.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002349","BK0239","BK0102"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2582217362","title":"精华制药（002349）披露公司产品获得药品注册证书，11月11日股价上涨0.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582217362","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582217362?lang=zh_cn&edition=full","pubTime":"2025-11-11 22:18","pubTimestamp":1762870703,"startTime":"0","endTime":"0","summary":"截至2025年11月11日收盘，精华制药报收于7.99元，较前一交易日上涨0.25%，最新总市值为66.29亿元。该股当日开盘7.96元，最高8.04元，最低7.89元，成交额达1.82亿元，换手率为2.8%。公司近日发布公告称，精华制药集团股份有限公司近日收到国家药品监督管理局核准签发的卡左双多巴缓释片两个规格的《药品注册证书》，分别为卡比多巴25mg/左旋多巴100mg和卡比多巴50mg/左旋多巴200mg，注册分类为化学药品4类。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111100040783.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0102","BK0239","002349"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2582356860","title":"精华制药(002349.SZ)：卡左双多巴缓释片获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2582356860","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582356860?lang=zh_cn&edition=full","pubTime":"2025-11-11 16:06","pubTimestamp":1762848393,"startTime":"0","endTime":"0","summary":"智通财经APP讯，精华制药 发布公告，近日，公司收到国家药品监督管理局核准签发的卡左双多巴缓释片的两个《药品注册证书》。公司卡左双多巴缓释片为国内第三家获批企业，卡左双多巴缓释片则为国内首仿且该规格原研产品没有在国内进行注册销售。公司卡左双多巴缓释片的成功获批，为帕金森病患者提供了比较好的原研替代产品，其中小规格的获批，为轻症患者的服药带来了便利性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1367729.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"精华制药(002349.SZ)：卡左双多巴缓释片获得药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002349","BK0239","BK0102"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2580231018","title":"股市必读：精华制药（002349）10月31日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2580231018","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580231018?lang=zh_cn&edition=full","pubTime":"2025-11-03 06:26","pubTimestamp":1762122371,"startTime":"0","endTime":"0","summary":"截至2025年10月31日收盘，精华制药报收于7.5元，上涨1.21%，换手率1.59%，成交量12.98万手，成交额9700.94万元。董秘最新回复投资者： 精华制药是中国产能最大的锂电池电解容剂二氧戊环企业，孙公司鲁化森萱有二氧五环产品，一直扩大产能，最近二氧戊环价格从13000涨至21000，大幅涨价是否属实？董秘： 孙公司鲁化森萱是国内二氧戊环主要优质供应商之一，该产品目前年产能为6000吨，近期销售价格相对平稳。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110300001382.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002349","BK0102","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517971030","title":"精华制药：为遵循信息披露公平原则,公司会在定期报告披露相对应时点股东人数","url":"https://stock-news.laohu8.com/highlight/detail?id=2517971030","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517971030?lang=zh_cn&edition=full","pubTime":"2025-03-06 08:57","pubTimestamp":1741222634,"startTime":"0","endTime":"0","summary":"证券之星消息，精华制药(002349)03月05日在投资者关系平台上答复投资者关心的问题。投资者提问：股东人数多少？精华制药回复：尊敬的投资者，为遵循信息披露公平原则,公司会在定期报告披露相对应时点股东人数。对其他各月股东人数,投资者可通过现场或电子邮件等方式向公司提供证明其持有公司股份的书面文件,公司经核实股东身份后按照要求予以提供。感谢您对公司的关心!以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025030600007479.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002349","BK0239","BK0102"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512260134","title":"精华制药：公司尚在进行项目前期可行性方案论证等工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2512260134","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512260134?lang=zh_cn&edition=full","pubTime":"2025-02-18 17:30","pubTimestamp":1739871010,"startTime":"0","endTime":"0","summary":"证券之星消息，精华制药(002349)02月18日在投资者关系平台上答复投资者关心的问题。投资者：请问董秘，贵司现代化基地啥进展了？精华制药董秘：公司尚在进行项目前期可行性方案论证等工作，有进展将及时履行信息披露义务。感谢您对公司的关心！以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025021800030490.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0102","BK0239","002349"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509759752","title":"精华制药：2023年度公司及下属子公司环境治理和保护的投入累积约2932万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2509759752","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509759752?lang=zh_cn&edition=full","pubTime":"2025-02-07 12:00","pubTimestamp":1738900813,"startTime":"0","endTime":"0","summary":"证券之星消息，精华制药02月06日在投资者关系平台上答复投资者关心的问题。我是一名城市公民。想请问贵公司在生产活动中，是否采取过一些有利于提升城市空气质量的措施？公民都期望生活在一个空气清新环境优美的地方。精华制药董秘：公司一向注重环境保护，2023年度，公司及下属子公司环境治理和保护的投入累积约2932万元，主要用于固废处置、废水预处理、废气治理设施运行、环境自行监测、项目环评编制、环保设施投入等。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025020700015568.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002349","164908","BK0102","399806","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2494012958","title":"精华制药收盘下跌2.60%，滚动市盈率29.59倍","url":"https://stock-news.laohu8.com/highlight/detail?id=2494012958","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2494012958?lang=zh_cn&edition=full","pubTime":"2024-12-25 16:54","pubTimestamp":1735116840,"startTime":"0","endTime":"0","summary":"12月25日，精华制药今日收盘7.87元，下跌2.60%，滚动市盈率PE达到29.59倍。从行业市盈率排名来看，公司所处的中药行业市盈率平均41.41倍，行业中值28.16倍，精华制药排名第45位。消息面上，精华制药5月10日接待深圳市安通私募证券基金管理有限公司等2家机构调研，上市公司接待人员包括董事会秘书王剑锋,证券事务代表樊屹秋。最新一期业绩显示，2024年三季报，公司实现营业收入10.45亿元，同比-6.65%；净利润1.64亿元，同比-15.93%，销售毛利率49.87%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2024/12/25165446798531.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["002349","BK0239","BK0102"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1777534559729,"stockEarnings":[{"period":"1week","weight":-0.0081},{"period":"1month","weight":-0.0054},{"period":"3month","weight":-0.0394},{"period":"6month","weight":-0.0253},{"period":"1year","weight":0.0687},{"period":"ytd","weight":0.0069}],"compareEarnings":[{"period":"1week","weight":0.0003},{"period":"1month","weight":0.047},{"period":"3month","weight":-0.0121},{"period":"6month","weight":0.0386},{"period":"1year","weight":0.2498},{"period":"ytd","weight":0.0349}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"精华制药集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"80720人(较上一季度减少3.79%)","perCapita":"10086股","listingDate":"2010-02-03","address":"江苏省南通市崇川区港闸经济开发区兴泰路9号","registeredCapital":"82967万元","survey":" 精华制药集团股份有限公司的主营业务是传统中成药制剂、化学原料药及中间体、化工医药中间体、中药材及中药饮片、大健康产品等的研发、生产和销售。公司的主要产品是王氏保赤丸、季德胜蛇药片、正柴胡饮颗粒、黄芪泡腾片、当归、白芍、苯巴比妥、氟尿嘧啶、二氧六环、甲基肼。","listedPrice":19.8},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"精华制药(002349)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供精华制药(002349)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"精华制药,002349,精华制药股票,精华制药股票老虎,精华制药股票老虎国际,精华制药行情,精华制药股票行情,精华制药股价,精华制药股市,精华制药股票价格,精华制药股票交易,精华制药股票购买,精华制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"精华制药(002349)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供精华制药(002349)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}